HCID 18361764, 화합물 → HCID 18361794, 화합물
반응식
Cl[C:2]1[C:11]2[C:6](=[CH:7][CH:8]=[CH:9][CH:10]=2)[C:5]2=[N:12][N:13]=[C:14]([C:15]3[CH:19]=[CH:18][O:17][N:16]=3)[N:4]2[N:3]=1.[OH:20][CH2:21][C:22]1[N:23]([CH2:27][O:28][CH2:29][CH2:30][Si:31]([CH3:34])([CH3:33])[CH3:32])[N:24]=[CH:25][N:26]=1>>[O:17]1[CH:18]=[CH:19][C:15]([C:14]2[N:4]3[N:3]=[C:2]([O:20][CH2:21][C:22]4[N:23]([CH2:27][O:28][CH2:29][CH2:30][Si:31]([CH3:34])([CH3:33])[CH3:32])[N:24]=[CH:25][N:26]=4)[C:11]4[C:6]([C:5]3=[N:12][N:13]=2)=[CH:7][CH:8]=[CH:9][CH:10]=4)=[N:16]1참가 물질
3
실험 절차
The title-compound was prepared from 6-chloro-3-(3-isoxazolyl)-1,2,4-triazolo[3,4-a]phthalazine (described in Example 34, part b) and 3-(hydroxymethyl)-2-{[2-(trimethylsilyl)ethoxy]methyl}-1,2,4-triazole (described in Example 45, part c) following the procedure described in Example 45, part d, 1H NMR (360 MHz, CDCl3) δ 0.00 (9H, s, 3 of CH3), 0.88 (2H, q, J=8.4 Hz, CH2), 3.67 (2H; t, J=8.3 Hz, CH2), 5.84 (2H, s, CH2), 5.92 (2H, s, CH2), 7.30 (1H, d, J=1.7 Hz, Ar—H), 7.89 (1H; t, J=7.1 Hz, Ar—H), 7.96 (1H, s, Ar—H), 8.02 (1H, t, J=7.6 Hz, Ar—H), 8.32 (1H, d, J=8.2 Hz, Ar—H), 8.70 (1H, s, Ar—H), 8.75 (1H, d, J=8.2 Hz, Ar—H).
출처 및 근거
- ORD 기록
- ord-9b19b118004d47eb94a7ccc25912f228
- 출처 데이터셋
- uspto-grants-2001_10